7/9/2020 | Regenerative Medicine Advanced Therapy Designation |
7/7/2020 | Summary of Safety and Effectiveness - Alinity m HIV-1 |
7/6/2020 | July 2, 2020 Approval Order - Alinity m HIV-1 |
7/6/2020 | July 2, 2020 Approval Letter - Flucelvax |
7/6/2020 | July 2, 2020 Approval Letter - Fluad and Fluad Quadrivalent |
7/6/2020 | July 2, 2020 Approval Letter - FluLaval |
7/2/2020 | July 2, 2020 Approval Letter - Afluria |
7/2/2020 | July 2, 2020 Approval Letter - Fluarix Quadrivalent |
7/2/2020 | July 2, 2020 Approval Letter - Flublok |
7/2/2020 | July 2, 2020 Approval Letter - Fluzone Quadrivalent and Fluzone High-Dose Quadrivalent |
7/2/2020 | Influenza Vaccine for the 2020-2021 Season |
7/2/2020 | Updated Information for Human Cell, Tissue, or Cellular or Tissue-based Product (HCT/P) Establishments Regarding the COVID-19 Pandemic |
7/2/2020 | Complete List of Licensed Products and Establishments |
7/2/2020 | Complete List of Substantially Equivalent 510(k) Device Applications |
7/2/2020 | Complete List of Currently Approved Premarket Approvals (PMAs) |
7/2/2020 | Complete List of Currently Approved NDA and ANDA Application Submissions |
7/2/2020 | Testing Human Cells, Tissues, and Cellular and Tissue Based Product (HCT/P) Donors for Relevant Communicable Disease Agents and Diseases |
7/1/2020 | Expiration Date Extension for MicRhoGAM (Rho(D) Immune Globulin) Lot MVP116A1 through July 19, 2021 |
6/30/2020 | Evaluation of Therapeutic Approaches Based on Genome Editing and Stem Cell Technologies |
6/30/2020 | Development and Licensure of Vaccines to Prevent COVID-19; Guidance for Industry |
6/29/2020 | Exceptions and Alternative Procedures Approved Under 21 CFR 640.120 |
6/26/2020 | June 26, 2020 Approval Letter - BeneFIX |
6/25/2020 | Summary Basis for Regulatory Action - Blood Grouping Reagent, Anti-Lea, Anti-Leb |
6/24/2020 | Guidance Agenda: Guidance Documents CBER is Planning to Publish During Calendar Year 2020 |
6/24/2020 | June 9, 2020 Clinical Review - GARDASIL 9 |
6/19/2020 | June 19, 2020 Approval Letter - Measles, Mumps, and Rubella Virus Vaccine Live |
6/19/2020 | June 18, 2020 Approval Letter - Blood Grouping Reagent, Anti-Lea (Murine Monoclonal)(For Further Manufacturing Use) |
6/19/2020 | June 18, 2020 Approval Letter - Blood Grouping Reagent, Anti-Leb (Murine Monoclonal)(For Further Manufacturing Use) |
6/19/2020 | BK190356 - PrepaCyte-CB Processing System |
6/18/2020 | eSubmitter Application History |
6/16/2020 | BK200474 - NEO Iris |
6/16/2020 | June 12, 2020 Approval Letter - Referencells |
6/16/2020 | June 12, 2020 Approval Letter - Panoscreen and Panoscreen Extend |
6/16/2020 | 2020 Biological License Application Supplement Noteworthy Approvals |
6/16/2020 | 2020 Biological Device Application Approvals |
6/16/2020 | CBER Vaccine ICSR Implementation |
6/16/2020 | CBER Vaccine ICSR (Legacy) Implementation |
6/16/2020 | Getting Started with ICSR Submission of FDA's electronic Vaccines Adverse Event Reporting System (eVAERS) |
6/16/2020 | Electronic Submission of Postmarket Safety Reports |
6/15/2020 | BK200479 - WellSky Blood - Emergency Issue 2020 R1 |
6/15/2020 | June 12, 2020 Approval Letter - Gardasil 9 |
6/12/2020 | Regenerative Medicine Fellowship under the Service Fellowship Program for CBER |
6/11/2020 | Assessing Immunogenicity of Products for Gene Therapy and T cell Therapy |
6/11/2020 | Investigating the Effects of Cell-Materials Interactions on the Safety and Effectiveness of Cell-Based Products |
6/11/2020 | June 9, 2020 Approval Letter - Kedbumin |
6/11/2020 | BK200475 - ALYX Component Collection System |
6/11/2020 | BK200482 - Blood Product Administration Module Version 3-2020 |
6/9/2020 | BK190393 - Aeon CPKit |
6/5/2020 | New Approaches to the Development and Evaluation of Human Cytomegalovirus (HCMV) Vaccines |
6/3/2020 | OraQuick In-Home HIV Test Fact Sheet |
No hay comentarios:
Publicar un comentario